Ongoing cancer research continues to impact the treatment and prognosis of Type I cancers positively. Advances in targeted therapies and immunotherapy offer new avenues for treatment, especially for cancers that may not respond well to traditional therapies. Clinical trials also provide opportunities for patients to access cutting-edge treatments that could potentially improve outcomes.
